Gudlavalleti Seshu K, Crawford Erika N, Tran Nhi N, Orten Dana J, Harder Jeffery D, Reddy Jeeri R
JN International Medical Corporation, 2720 N 84th Street, Omaha, NE 68134, United States.
JN International Medical Corporation, 2720 N 84th Street, Omaha, NE 68134, United States.
J Pharm Biomed Anal. 2015 Mar 25;107:432-6. doi: 10.1016/j.jpba.2015.01.034. Epub 2015 Jan 25.
The ability to accurately measure and report trace amounts of residual formaldehyde impurity in a vaccine product is not only critical in the product release but also a regulatory requirement. In many bacterial or viral vaccine manufacturing procedures, formaldehyde is used either at a live culture inactivation step or at a protein de-toxification step or at both. Reported here is a validated and improved C18-UPLC method (developed based on previously published C-8 HPLC method) to determine the traces of formaldehyde process impurity in a liquid form Neisseria meningitidis A/C/Y/W-135-DT conjugate vaccine formulated in isotonic aqueous 1× PBS. UPLC C-18 column and the conditions described distinctly resolved the 2,4-DNPH-HCHO adduct from the un-reacted 2,4-DNPH as detected by TUV detector at 360 nm. This method was shown to be compatible with PBS formulation and extremely sensitive (with a quantitation limit of 0.05 ppm) and aided to determine formaldehyde contamination sources by evaluating the in-process materials as a track-down analysis. Final nanogram levels of formaldehyde in the formulated single dose vialed vaccine mainly originated from the diphtheria toxoid carrier protein used in the production of the conjugate vaccine, whereas relative contribution from polysaccharide API was minimal.
准确测量和报告疫苗产品中痕量残留甲醛杂质的能力不仅在产品放行中至关重要,也是一项监管要求。在许多细菌或病毒疫苗生产程序中,甲醛用于活培养物灭活步骤、蛋白质解毒步骤或两者兼用。本文报道了一种经过验证和改进的C18-UPLC方法(基于先前发表的C-8 HPLC方法开发),用于测定以等渗水性1× PBS配制的液体形式的A/C/Y/W-135-DT脑膜炎奈瑟菌结合疫苗中的痕量甲醛工艺杂质。UPLC C-18柱及所述条件在360 nm处通过TUV检测器检测时,能将2,4-DNPH-HCHO加合物与未反应的2,4-DNPH清晰分离。该方法被证明与PBS制剂兼容且极其灵敏(定量限为0.05 ppm),并通过评估过程中的物料作为追踪分析来辅助确定甲醛污染来源。配制好的单剂量瓶装疫苗中最终的纳克级甲醛主要源自结合疫苗生产中使用的白喉类毒素载体蛋白,而多糖原料药的相对贡献极小。